ArticleBreast care (Basel, Switzerland)2020
Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel.
Article in Breast care (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The RESILIENT Study: A Retrospective, Descriptive, Correlational Investigation of Correlates of Oral Endocrine Therapy Adherence in Older Women With Breast Cancer.Cancer medicine · 2026Article
- The impact of COVID-19 pandemic on treatment adherence of patients with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Influencing Factors of Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients: A Meta-Analysis.Health science reports · 2025Review
- Review
- Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.British journal of clinical pharmacology · 2023Article
- Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.Journal of breast cancer · 2023Article
- Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.Breast cancer research and treatment · 2023Article
- Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients.Journal of cancer research and clinical oncology · 2023Article
- Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.European journal of cancer care · 2022Article
- Using data mining technology to predict medication-taking behaviour in women with breast cancer: A retrospective study.Nursing open · 2022Article
- Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Response To Letter].Patient preference and adherence · 2022Article
- Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Letter].Patient preference and adherence · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant hormonal therapy (HT) has been consistently proven to improve multiple outcomes in early breast cancer yet rates of adherence and persistence are variable.
methodsWe retrospectively identified women diagnosed with nonmetastatic breast cancer and initiating HT between January 2000 and December 2007 in a large Israeli health provider. Prescription records including the drug name, date of purchase, and the quantity of pills dispensed were collected. We used Cox proportional hazards and binary logistic models to analyze factors associated with early discontinuation (<5 years) and nonadherence (proportion of days covered, PDC <80%) of HT, respectively.
resultsA total of 4,178 women with breast cancer were identified with nearly 95% of patients treated with tamoxifen as the initial HT. Over the 5-year follow-up period, early discontinuation was identified in 955 (23%) patients. The mean PDC was 82.9% (SD 0.004). Younger age and low BMI were both associated with an increased risk of early discontinuation and nonadherence. A history of hypertension was associated with a higher likelihood of both outcomes.
conclusionAdherence and persistence with HT among Israeli breast cancer survivors are comparable to those in international reports. Interventions are necessary to identify and prevent suboptimal HT adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.